Viridian Therapeutics, Inc.\DE·4

Nov 13, 5:17 PM ET

Harmon Seth 4

4 · Viridian Therapeutics, Inc.\DE · Filed Nov 13, 2023

Insider Transaction Report

Form 4
Period: 2023-11-10
Harmon Seth
Chief Financial Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-11-10+270,000270,000 total
    Exercise: $13.76Exp: 2033-11-10Common Stock (270,000 underlying)
Footnotes (1)
  • [F1]The option vests in equal monthly installments through November 10, 2027, subject to the Reporting Person's continued service to Issuer through each vesting date.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4